Philip S. Bernard

Philip S. Bernard, MD

Languages spoken: English

Academic Information

Departments Adjunct - Pathology

Lab

Board Certification

  • National Board of Medical Examiners
  • American Board of Pathology (Clinical Path)

Philip Bernard, MD, is an associate professor of pathology at the University of Utah School of Medicine, medical director of the Molecular Oncology Dx, and a Huntsman Cancer Institute investigator. He is a member of the Experimental Therapeutics Program.

Bernard's research focuses on molecular classifications of solid tumors for prognosis and treatment. Using cutting-edge technology, his lab correlates clinical behavior of tumors with molecular features. His group was instrumental in the development of the PAM50 (Prosigna) breast cancer subtyping test for prognosis in early stage disease (link to ARUP CME on this topic). Along with expression profiling and DNA analyses of solid tumors, his lab is now investigating a variety of techniques to identify circulating biomarkers for screening and monitoring cancers.

Education History

Undergraduate University of Utah
 BS
Professional Medical University of Utah
 MD
Research Fellow Carl T. Wittwer, MD, PhD
 Research Fellow
Residency University of Utah School of Medicine
 Resident

Selected Publications

Journal Article

  1. Liu J, Welm B, Boucher KM, Ebbert MT, Bernard P (2012). TRIM29 functions as a tumor suppressor in nontumorigenic breast cells and invasive ER+ breast cancer. The American journal of pathology, 180(2), 839-47. (Read full article)
  2. Ma CX, Ellis MJ, Petroni GR, Guo Z, Cai SR, Ryan CE, Craig Lockhart A, Naughton MJ, Pluard TJ, Brenin CM, Picus J, Creekmore AN, Mwandoro T, Yarde ER, Reed J, Ebbert M, Bernard PS, Watson M, Doyle LA, Dancey J, Piwnica-Worms H, Fracasso P (2013). A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. Breast cancer research and treatment, 137(2), 483-92. (Read full article)
  3. Martin M, Prat A, Rodriguez-Lescure A, Caballero R, Ebbert MT, Munarriz B, Ruiz-Borrego M, Bastien RR, Crespo C, Davis C, Rodriguez CA, Lopez-Vega JM, Furio V, Garcia AM, Casas M, Ellis MJ, Berry DA, Pitcher BN, Harris L, Ruiz A, Winer E, Hudis C, Stijleman IJ, Tuck DP, Carrasco E, Perou CM, Bernard P (2013). PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast cancer research and treatment, 138(2), 457-66. (Read full article)
  4. Prat A, Parker JS, Fan C, Cheang MC, Miller LD, Bergh J, Chia SK, Bernard PS, Nielsen TO, Ellis MJ, Carey LA, Perou C (2012). Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Annals of oncology, 23(11), 2866-73. (Read full article)
  5. Caan BJ, Sweeney C, Habel LA, Kwan ML, Kroenke CH, Weltzien EK, Quesenberry CP Jr, Castillo A, Factor RE, Kushi LH, Bernard P (2014). Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes. Cancer epidemiology, biomarkers & prevention, 23(5), 725-34. (Read full article)
  6. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen T (2009). Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. Journal of the National Cancer Institute, 101(10), 736-50. (Read full article)
  7. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard P (2009). Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of clinical oncology, 27(8), 1160-7. (Read full article)
  8. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer E (2012). TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. Journal of clinical oncology, 30(21), 2615-23. (Read full article)
  9. Prat A, Cheang MC, Martin M, Parker JS, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO, Perou C (2013). Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. Journal of clinical oncology, 31(2), 203-9. (Read full article)
  10. Won JR, Gao D, Chow C, Cheng J, Lau SY, Ellis MJ, Perou CM, Bernard PS, Nielsen T (2013). A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard. Modern pathology, 26(11), 1438-50. (Read full article)
  11. Al-Tamimi DM, Bernard PS, Shawarby MA, Al-Amri AM, Hadi M (2009). Distribution of molecular breast cancer subtypes in middle eastern-saudi arabian women: a pilot study. Ultrastructural pathology, 33(4), 141-50. (Read full article)
  12. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E, Neumayer L, Randall RL, Stijleman IJ, Welm BE, Welm A (2011). Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nature medicine, 17(11), 1514-20. (Read full article)
  13. Wilkerson MD, Yin X, Hoadley KA, Liu Y, Hayward MC, Cabanski CR, Muldrew K, Miller CR, Randell SH, Socinski MA, Parsons AM, Funkhouser WK, Lee CB, Roberts PJ, Thorne L, Bernard PS, Perou CM, Hayes D (2010). Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clinical cancer research, 16(19), 4864-75. (Read full article)
  14. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, Cheang MC, Mardis ER, Perou CM, Bernard PS, Ellis M (2010). A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clinical cancer research, 16(21), 5222-32. (Read full article)
  15. Cheang MC, Voduc KD, Tu D, Jiang S, Leung S, Chia SK, Shepherd LE, Levine MN, Pritchard KI, Davies S, Stijleman IJ, Davis C, Ebbert MT, Parker JS, Ellis MJ, Bernard PS, Perou CM, Nielsen T (2012). Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clinical cancer research, 18(8), 2402-12. (Read full article)
  16. Chia SK, Bramwell VH, Tu D, Shepherd LE, Jiang S, Vickery T, Mardis E, Leung S, Ung K, Pritchard KI, Parker JS, Bernard PS, Perou CM, Ellis MJ, Nielsen T (2012). A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clinical cancer research, 18(16), 4465-72. (Read full article)
  17. Kelly CM, Bernard PS, Krishnamurthy S, Wang B, Ebbert MT, Bastien RR, Boucher KM, Young E, Iwamoto T, Pusztai (2012). Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX(R)) and the PAM50 breast cancer intrinsic Classifier in early-stage estrogen receptor-positive breast cancer. The oncologist, 17(4), 492-8. (Read full article)
  18. Wilkerson MD, Schallheim JM, Hayes DN, Roberts PJ, Bastien RR, Mullins M, Yin X, Miller CR, Thorne LB, Geiersbach KB, Muldrew KL, Funkhouser WK, Fan C, Hayward MC, Bayer S, Perou CM, Bernard P (2013). Prediction of lung cancer histological types by RT-qPCR gene expression in FFPE specimens. The Journal of molecular diagnostics, 15(4), 485-97. (Read full article)
  19. Irvin WJ Jr, Orlowski RZ, Chiu WK, Carey LA, Collichio FA, Bernard PS, Stijleman IJ, Perou C, Ivanova A, Dees E (2010). Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer. Clinical breast cancer, 10(6), 465-70. (Read full article)
  20. Bastien RR, Rodriguez-Lescure A, Ebbert MT, Prat A, Munarriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson D, Lyons B, Alvarez I, Dowell T, Wall D, Segui MA, Barley L, Boucher KM, Alba E, Pappas L, Davis CA, Aranda I, Fauron C, Stijleman IJ, Palacios J, Anton A, Carrasco E, Caballero R, Ellis MJ, Nielsen TO, Perou CM, Astill M, Bernard PS, Martin (2012). PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC medical genomics, 5, 44. (Read full article)
  21. Cannon-Albright LA, Cooper KG, Georgelas A, Bernard P (2011). High quality and quantity Genome-wide germline genotypes from FFPE normal tissue. BMC research notes, 4, 159. (Read full article)
  22. Smith BA, Shelton DN, Kieffer C, Milash B, Usary J, Perou CM, Bernard PS, Welm B (2012). Targeting the PyMT Oncogene to Diverse Mammary Cell Populations Enhances Tumor Heterogeneity and Generates Rare Breast Cancer Subtypes. Genes & cancer, 3(9-10), 550-63. (Read full article)
  23. Ebbert MT, Bastien RR, Boucher KM, Martin M, Carrasco E, Caballero R, Stijleman IJ, Bernard PS, Facelli J (2011). Characterization of uncertainty in the classification of multivariate assays: application to PAM50 centroid-based genomic predictors for breast cancer treatment plans. Journal of clinical bioinformatics, 1, 37. (Read full article)

Letter

  1. Perou CM, Parker JS, Prat A, Ellis MJ, Bernard P (2010). Clinical implementation of the intrinsic subtypes of breast cancer. The Lancet. Oncology, 11(8), 718-9; author reply 720-1. (Read full article)